Growth hormone replacement therapy in medulloblastoma survivors: Editorial
Neuro-Oncology Pediatrics · 2025
DOI: 10.1093/neuped/wuaf010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Pediatrics, 2025. Verfasst von Maya Beth Lodish und 1 weiteren Autor:innen. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Treatment for medulloblastoma with craniospinal irradiation (081) can lead to growth hormone deficiency (GHD) in up to 70% of treated individuals; the development of GHD is related to the dose of radiation to the hypothalamus.1 As clinicians we are often faced with the concerned family who is weighing the risks and benefits of treating their child with growth hormone on the background of having had intensive therapy. Fortunately, data from multicenter studies have not found significant associations between GH replacement and cancer recurrence or mortality among childhood brain cancer survivors.2 We do know that certain factors, including high-grade or metastatic disease and younger age at treatment with craniospinal irradiation (CSI), increase the chance of disease recurrence, but the risk is primarily attributable to these baseline characteristics rather than to growth hormone therapy itself. Indeed, the CCSS showed that pediatric cancer survivors with medulloblastoma who were treated with GH replacement had a decreased risk of recurrence compared to those who were untreated (RR 0.13, 95% Cl 0.02-0.94, P = .04).3 This view is also reinforced by a soon-to-be-published IGHG recommendation on the use of growth hormone post-treatment for childhood brain tumors. Over the past two decades, advances in DNA sequencing and methylation assays have led to the formal recognition of four molecular subgroups of medulloblastoma: WNT activated, SHH activated, Group 3, and Group 4.4 Our understanding of the differences in behavior of subgroups of medulloblastoma continues to evolve into cancer treatment protocols that are risk-stratified3 For example, because children with distinct molecular subtypes have different long-term outcomes, the recommendations for CSI dosing as well as the intensity of chemotherapy continue to change over time. The current manuscript in Neuro-Oncology Pediatrics “Growth hormone replacement therapy does not predict relapse across medulloblastoma subgroups” by Bellon et al from the Hospital for Sick Children in Toronto, Canada is a retrospective observational cohort study over 23 years for 148 patients who were treated with CSI as children for a diagnosis of medulloblastoma at their institution. Patients were classified by molecular subgroups (WNT, SHH, group 4, group 3). 79 (53.4%) of patients were diagnosed with GH deficiency, of those 73 initiated treatment with GH. They found no associations between molecular subgroup and the likelihood of developing GHD. 34 patients relapsed during follow up, 10 of them had received GH. Contrary to concerns raised about the safety of GH treatment, in their multivariate analysis of patients without relapse >2 years post diagnosis, GH replacement was associated with improved overall survival (HR 0.34, 95% Cl 0.12-0.99, P = .049). The current study shows that the use of physiologic GH replacement therapy does not increase the risk of cancer recurrence or death in children with medulloblastoma treated with CSI. It is impactful in that it is the largest study of children with medulloblastoma who have been treated with GH, taking into account the molecular subtype of tumor. While the authors found that the likelihood of developing GH deficiency was not different among molecular subgroups or in the presence of metastatic disease, the current study might be underpowered to find differences among these groups. Also, newer guidelines for treatment of medulloblastoma involve differing doses for CSI in different histologic subtypes. We may expect that those patients who receive more intense treatment with higher doses of CSI would be more likely to experience radiation-induced GHD. The authors also mention that selection bias does affect who is a candidate for receiving GH, as patients with early relapse are not candidates. Regardless of these limitations, this article adds to the existing literature demonstrating that GH replacement is safe and beneficial for pediatric cancer survivors. We should continue to follow existing surveillance protocols with periodic clinical assessment for growth and endocrine disorders in order to detect growth failure and other endocrine sequelae.5 The current study supports the safety of long-term GH replacement in children treated for medulloblastoma, however, future larger-scale meta-analyses and international prospective trials are warranted. No funding sources to report for this manuscript. No conflict of interest to report for this manuscript. Maya E. Lodish (Writing—original draft)
Zitieren
APA
Lodish, M. B., & Bailey, S. (2025). Growth hormone replacement therapy in medulloblastoma survivors: Editorial. Neuro-Oncology Pediatrics. https://doi.org/10.1093/neuped/wuaf010
Vancouver
Lodish MB, Bailey S. Growth hormone replacement therapy in medulloblastoma survivors: Editorial. Neuro-Oncology Pediatrics. 2025. doi:10.1093/neuped/wuaf010
BibTeX
@article{Lodish2025,
author = {Lodish, Maya Beth and Bailey, Simon},
title = {Growth hormone replacement therapy in medulloblastoma survivors: Editorial},
journal = {Neuro-Oncology Pediatrics},
year = {2025},
doi = {10.1093/neuped/wuaf010}
}
EUVIMED